Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey, and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% (n = 103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Premedication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1-2 HSRs to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3-4 HSRs to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSRs in gynecologic cancer. Our study showed that HSRs in gynecologic cancer are common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSRs in gynecologic cancer was highlighted.

2 Department of Obstetrics and Gynecology Medical University of Warsaw 02 091 Warsaw Poland

Cancer Center Cantonal Hospital Baselland Medical University Clinic 4410 Liestal Switzerland

Department for Gynaecological and Breast Oncology University Medical Centre Maribor 2000 Maribor Slovenia

Department of Biomedicine University of Basel 4031 Basel Switzerland

Department of Global Health Koç University Graduate School of Health Sciences 34010 Istanbul Turkey

Department of Gynecologic Oncology Ankara City Hospital 06680 Ankara Turkey

Department of Gynecology and Gynecologic Oncology Evangelische Kliniken Essen Mitte 45136 Essen Germany

Department of Obstetrics and Gynecology Klinikum Friedrichshafen Medizin Campus Bodensee 88048 Friedrichshafen Germany

Department of Obstetrics and Gynecology Klinikum Mittelbaden Academic Teaching Hospital of Heidelberg University 76532 Baden Baden Germany

Department of Obstetrics and Gynecology University Hospitals Schleswig Holstein Campus Kiel 24105 Kiel Germany

Department of Obstetrics and Gynecology University of Zielona Gora 65 729 Zielona Gora Poland

Department of Women's and Children's Health Karolinska Institutet 171 77 Stockholm Sweden

Division of Gynaecologic Oncology 1st Department of Obstetrics and Gynaecology Alexandra Hospital National and Kapodistrian University of Athens School of Health Sciences 116 35 Athens Greece

Division of Gynecologic Oncology Department of Gynecology and Obstetrics Frankfurt Goethe University Hospital Theodor Stern Kai 7 60590 Frankfurt Germany

ESGO Office 110 00 Prague Czech Republic

Gynecological Cancer Center University Hospital Basel 4031 Basel Switzerland

Peter MacCallum Cancer Center East Melbourne VIC 3002 Australia

The OncoAlert Network 22185 Lund Sweden

UOC Ginecologia Oncologica Dipartimento di Scienze della Salute della Donna del Bambino e di Sanità Pubblica Fondazione Policlinico Universitario Agostino Gemelli IRCCS 00168 Rome Italy

Zobrazit více v PubMed

Oaknin A., Bosse T., Creutzberg C., Giornelli G., Harter P., Joly F., Lorusso D., Marth C., Makker V., Mirza M., et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022;33:860–877. doi: 10.1016/j.annonc.2022.05.009. PubMed DOI

Ledermann J.A., Matias-Guiu X., Amant F., Concin N., Davidson B., Fotopoulou C., González-Martin A., Gourley C., Leary A., Lorusso D., et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease. Ann. Oncol. 2024;35:248–266. doi: 10.1016/j.annonc.2023.11.015. PubMed DOI

González-Martín A., Harter P., Leary A., Lorusso D., Miller R., Pothuri B., Ray-Coquard I., Tan D., Bellet E., Oaknin A., et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023;34:833–848. doi: 10.1016/j.annonc.2023.07.011. PubMed DOI

Marth C., Landoni F., Mahner S., McCormack M., Gonzalez-Martin A., Colombo N., Committee E.G. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018;29((Suppl. S4)):iv262. doi: 10.1093/annonc/mdy160. PubMed DOI

Falzone L., Bordonaro R., Libra M. SnapShot: Cancer chemotherapy. Cell. 2023;186:1816.e1. doi: 10.1016/j.cell.2023.02.038. DOI

Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364–378. doi: 10.1016/j.ejphar.2014.07.025. PubMed DOI PMC

Maloney S.M., Hoover C.A., Morejon-Lasso L.V., Prosperi J.R. Mechanisms of Taxane Resistance. Cancers. 2020;12:3323. doi: 10.3390/cancers12113323. PubMed DOI PMC

Zhang C., Xu C., Gao X., Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12:2115–2132. doi: 10.7150/thno.69424. PubMed DOI PMC

Castells M., Sancho-Serra Mdel C., Simarro M. Hypersensitivity to antineoplastic agents: Mechanisms and treatment with rapid desensitization. Cancer Immunol. Immunother. 2012;61:1575–1584. doi: 10.1007/s00262-012-1273-x. PubMed DOI PMC

O’Malley D.M., Vetter M.H., Cohn D.E., Khan A., Hays J.L. Outpatient desensitization in selected patients with platinum hypersensitivity reactions. Gynecol. Oncol. 2017;145:603–610. doi: 10.1016/j.ygyno.2017.03.015. PubMed DOI

Moon D.H., Lee J.M., Noonan A.E., Annunziata C.M., Minasian L., Houston N., Hays J.L., Kohn E.C. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br. J. Cancer. 2013;109:1072–1078. doi: 10.1038/bjc.2013.389. PubMed DOI PMC

Pagani M., Bavbek S., Alvarez-Cuesta E., Dursun A.B., Bonadonna P., Castells M., Cernadas J., Chiriac A., Sahar H., Madrigal-Burgaleta R., et al. Hypersensitivity reactions to chemotherapy: An EAACI Position Paper. Allergy. 2022;77:388–403. doi: 10.1111/all.15113. PubMed DOI

Boulanger J., Boursiquot J.N., Cournoyer G., Lemieux J., Masse M.S., Almanric K., Guay M.P. Management of hypersensitivity to platinum- and taxane-based chemotherapy: Cepo review and clinical recommendations. Curr. Oncol. 2014;21:e630–e641. doi: 10.3747/co.21.1966. PubMed DOI PMC

Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: Symptoms, pathomechanism, reexposure, and desensitization. Med. Clin. N. Am. 2010;94:835–852, xiii. doi: 10.1016/j.mcna.2010.03.002. PubMed DOI

Dizon D.S., Sabbatini P.J., Aghajanian C., Hensley M.L., Spriggs D.R. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol. Oncol. 2002;84:378–382. doi: 10.1006/gyno.2001.6519. PubMed DOI

Cernadas J.R., Brockow K., Romano A., Aberer W., Torres M.J., Bircher A., Campi P., Sanz M.L., Castells M., Demoly P., et al. General considerations on rapid desensitization for drug hypersensitivity—A consensus statement. Allergy. 2010;65:1357–1366. doi: 10.1111/j.1398-9995.2010.02441.x. PubMed DOI

Vetter M.H., Khan A., Backes F.J., Bixel K., Cohn D.E., Copeland L.J., Fowler J.M., Salani R., Li Q., O’Malley D.M. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol. Oncol. 2019;152:316–321. doi: 10.1016/j.ygyno.2018.10.037. PubMed DOI

Scherer K., Brockow K., Aberer W., Gooi J.H.C., Demoly P., Romano A., Schnyder B., Whitaker P., Cernadas J.S.R., Bircher A.J., et al. Desensitization in delayed drug hypersensitivity reactions—An EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013;68:844–852. doi: 10.1111/all.12161. PubMed DOI

Zwimpfer T.A., Scherer K., Schotzau A., Heinzelmann-Schwarz V., Hartmann K., Vetter M., Montavon C. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers. Cancer Med. 2023;13:e6840. doi: 10.1002/cam4.6840. PubMed DOI PMC

Rosello S., Blasco I., Garcia Fabregat L., Cervantes A., Jordan K., Committee E.G. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 2017;28((Suppl. S4)):iv100–iv118. doi: 10.1093/annonc/mdx216. PubMed DOI

Tsao L.R., Young F.D., Otani I.M., Castells M.C. Hypersensitivity Reactions to Platinum Agents and Taxanes. Clin. Rev. Allergy Immunol. 2022;62:432–448. doi: 10.1007/s12016-021-08877-y. PubMed DOI PMC

Sloane D., Govindarajulu U., Harrow-Mortelliti J., Barry W., Hsu F.I., Hong D., Laidlaw T., Palis R., Legere H., Bunyavanich S., et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J. Allergy Clin. Immunol. Pract. 2016;4:497–504. doi: 10.1016/j.jaip.2015.12.019. PubMed DOI

Koshiba H., Hosokawa K., Kubo A., Miyagi Y., Oda T., Watanabe A., Honjo H. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int. J. Gynecol. Cancer. 2009;19:460–465. doi: 10.1111/IGC.0b013e3181a1bf2e. PubMed DOI

Sendo T., Sakai N., Itoh Y., Ikesue H., Kobayashi H., Hirakawa T., Nakano H., Oishi R. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother. Pharmacol. 2005;56:91–96. doi: 10.1007/s00280-004-0924-9. PubMed DOI

Kessous R., Wissing M.D., Laskov I., Abitbol J., Bitharas J., Agnihotram V.R., Yasmeen A., Salvador S., Lau S., Gotlieb W.H. Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival. Int. J. Cancer. 2021;148:2304–2312. doi: 10.1002/ijc.33395. PubMed DOI

Shepherd G.M. Hypersensitivity reactions to chemotherapeutic drugs. Clin. Rev. Allergy Immunol. 2003;24:253–262. doi: 10.1385/CRIAI:24:3:253. PubMed DOI

Altwerger G., Florsheim E.B., Menderes G., Black J., Schwab C., Gressel G.M., Nelson W.K., Carusillo N., Passante T., Huang G., et al. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. J. Cancer Res. Clin. Oncol. 2018;144:2449–2456. doi: 10.1007/s00432-018-2753-y. PubMed DOI

Falzone L., Scandurra G., Lombardo V., Gattuso G., Lavoro A., Distefano A.B., Scibilia G., Scollo P. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review) Int. J. Oncol. 2021;59:53. doi: 10.3892/ijo.2021.5233. PubMed DOI PMC

Berardi R., Morgese F., Rinaldi S., Torniai M., Mentrasti G., Scortichini L., Giampieri R. Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management. Cancer Manag. Res. 2020;12:9363–9374. doi: 10.2147/CMAR.S220976. PubMed DOI PMC

Pillay B., Wootten A.C., Crowe H., Corcoran N., Tran B., Bowden P., Crowe J., Costello A.J. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev. 2016;42:56–72. doi: 10.1016/j.ctrv.2015.11.007. PubMed DOI

Heudel P.E., Devouassoux-Shisheboran M., Taieb S., Genestie C., Selle F., Morice P., Rouzier R., Ray-Coquard I. Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy. Eur. J. Gynaecol. Oncol. 2017;38:175–180. PubMed

Bjorn S.F., Schnack T.H., Lajer H., Christensen I.J., Lundvall L., Thomsen L.N., Hogdall C. Classification of Ovarian Cancer Surgery Facilitates Treatment Decisions in a Gynecological Multidisciplinary Team. Int. J. Gynecol. Cancer. 2017;27:382–389. doi: 10.1097/IGC.0000000000000876. PubMed DOI

Moterani V.C., Tiezzi D.G., de Andrade J.M., Candido Dos Reis F.J. Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort. J. Surg. Oncol. 2020;122:1802–1807. doi: 10.1002/jso.26186. PubMed DOI

Wright J.D., Chen L., Hou J.Y., Burke W.M., Tergas A.I., Ananth C.V., Neugut A.I., Hershman D.L. Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. Obstet. Gynecol. 2017;130:545–553. doi: 10.1097/AOG.0000000000002164. PubMed DOI PMC

Vernooij F., Heintz A.P., Coebergh J.W., Massuger L.F., Witteveen P.O., van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol. Oncol. 2009;112:455–461. doi: 10.1016/j.ygyno.2008.11.011. PubMed DOI

Scott R., Hawarden A., Russell B., Edmondson R.J. Decision-Making in Gynaecological Oncology Multidisciplinary Team Meetings: A Cross-Sectional, Observational Study of Ovarian Cancer Cases. Oncol. Res. Treat. 2020;43:70–77. doi: 10.1159/000504260. PubMed DOI